Acetylcholinesterase, butyrylcholinesterase and paraoxonase 1 activities in rats treated with cannabis, tramadol or both

Asian Pacific Journal of Tropical Medicine

Volumn 9, Issue 11, 2016, Pages 1089-1094

  Abdel Salam, Omar M E ^a   Youness, Eman R ^a   Khadrawy, Yasser A ^a   Sleem, Amany A ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Cannabis sativa; Cholinesterases; Cognitive decline; Memory; Tramadol

Indexed keywords

ACETYLCHOLINESTERASE; ARYLDIALKYLPHOSPHATASE 1; CANNABIS; CHOLINESTERASE; SODIUM CHLORIDE; TRAMADOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; COGNITION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; MALE; MEMORY DISORDER; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

EID: 84997079852     PISSN: 19957645     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apjtm.2016.09.009     Document Type: Article

References (51)

1. [1] Volkow, N.D., Baler, R.D., Compton, W.M., Weiss, S.R.B., Adverse health effects of marijuana use. N Engl J Med 370 (2014), 2219–2227.
2. [2] Desrosiers, N.A., Ramaekers, J.G., Chauchard, E., Gorelick, D.A., Huestis, M.A., Smoked cannabis’ psychomotor and neurocognitive effects in occasional and frequent smokers. J Anal Toxicol 39:4 (2015), 251–261.
3. [3] Maldonado, R., Berrendero, F., Ozaita, A., Robledo, P., Neurochemical basis of cannabis addiction. Neuroscience 181 (2011), 1–17.
4. [4] McClure, E.A., Lydiard, J.B., Goddard, S.D., Gray, K.M., Objective and subjective memory ratings in cannabis-dependent adolescents. Am J Addict 24:1 (2015), 47–52.
5. [5] Riba, J., Valle, M., Sampedro, F., Rodríguez-Pujadas, A., Martínez-Horta, S., Kulisevsky, J., et al. Telling true from false: cannabis users show increased susceptibility to false memories. Mol Psychiatry 20:6 (2015), 772–777.
6. [6] Battistella, G., Fornari, E., Annoni, J.M., Chtioui, H., Dao, K., Fabritius, M., et al. Long-term effects of cannabis on brain structure. Neuropsychopharmacology 39:9 (2014), 2041–2048.
7. [7] Chan, G.C., Hinds, T.R., Impey, S., Storm, D.R., Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. J Neurosci 18:14 (1998), 5322–5332.
8. [8] Abdel-Salam, O.M.E., Youness, E.R., Shaffee, N., Biochemical, immunological, DNA and histopathological changes caused by Cannabis sativa in the rat. J Neurol Epidemiol 2 (2014), 6–16.
9. [9] El-Remessy, A.B., Khalil, I.E., Matragoon, S., Abou-Mohamed, G., Tsai, N.J., Roon, P., et al. Neuroprotective effect of (-) Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. Am J Pathol 163:5 (2003), 1997–2008.
10. [10] Elsohly, M.A., Slade, D., Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 78:5 (2005), 539–548.
11. [11] Pertwee, R.G., Pharmacological actions of cannabinoids. Handb Exp Pharmacol 168 (2005), 1–51.
12. [12] Di Marzo, V., Stella, N., Zimmer, A., Endocannabinoid signalling and the deteriorating brain. Nat Rev Neurosci 16:1 (2015), 30–42.
13. [13] Bloms-Funke, P., Dremencov, E., Cremers, T.I., Tzschentke, T.M., Tramadol increases extracellular levels of serotonin and noradrenaline as measured by in vivo microdialysis in the ventral hippocampus of freely-moving rats. Neurosci Lett 490 (2011), 191–195.
14. [14] Grond, S., Sablotzki, A., Clinical pharmacology of tramadol. Clin Pharmacokinet 43:13 (2004), 879–923.
15. [15] Tjäderborn, M., Jönsson, A.K., Sandström, T.Z., Ahlner, J., Hägg, S., Non-prescribed use of psychoactive prescription drugs among drug-impaired drivers in Sweden. Drug Alcohol Depend 161 (2016), 77–85.
16. [16] Randall, C., Crane, J., Tramadol deaths in Northern Ireland: a review of cases from 1996 to 2012. J Forensic Leg Med 23 (2014), 32–36.
17. [17] El-Hadidy, M.A., Helaly, A.M., Medical and psychiatric effects of long-term dependence on high dose of tramadol. Subst Use Misuse 50:5 (2015), 582–589.
18. [18] Hosseini-Sharifabad, A., Rabbani, M., Sharifzadeh, M., Bagheri, N., Acute and chronic tramadol administration impair spatial memory in rat. Res Pharm Sci 11:1 (2016), 49–57.
19. [19] Loffredo, C.A., Boulos, D.N., Saleh, D.A., Jillson, I.A., Garas, M., Loza, N., et al. Substance use by Egyptian youth: current patterns and potential avenues for prevention. Subst Use Misuse 50:5 (2015), 609–618.
20. [20] Berge, J., Håkansson, A., Berglund, M., Alcohol and drug use in groups of cannabis users: results from a survey on drug use in the Swedish general population. Am J Addict 23:3 (2014), 272–279.
21. [21] Schliebs, R., Arendt, T., The cholinergic system in aging and neuronal degeneration. Behav Brain Res 221:2 (2011), 555–563.
22. [22] Campos, C., Rocha, N.B., Vieira, R.T., Rocha, S.A., Telles-Correia, D., Paes, F., et al. Treatment of cognitive deficits in Alzheimer's disease: a psychopharmacological review. Psychiatr Danub 28:1 (2016), 2–12.
23. [23] Massoulié, J., Sussman, J., Bon, S., Silman, I., Structure and functions of acetylcholinesterase and butyrylcholinesterase. Prog Brain Res 98 (1993), 139–146.
24. [24] Furlong, C.E., Paraoxonases: an historical perspective. Mackness, B., Mackness, M., Aviram, M., Paragh, G., (eds.) The paraoxonases: their role in disease development and xenobiotic metabolism, 2008, Springer, Dordrecht, 3–31.
25. [25] Menini, T., Gugliucci, A., Paraoxonase 1 in neurological disorders. Redox Rep 19:2 (2014), 49–58.
26. [26] Turner, J.C., Mahlberg, P.G., Separation of acid and neutral cannabinoids in Cannabis sativa L. using HPLC. Agurell, S., Dewey, W.L., Willete, R.E., (eds.) Chemical pharmacol ther agents, 1984, Academic Press, USA, 79–88.
27. [27] Ellman, G.L., Courtney, K.D., Andreas, V. Jr., Feather-Stone, R.M., A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharm 7 (1961), 88–90.
28. [28] Gorun, V., Proinov, I., Baltescu, V., Balaban, G., Barzu, O., Modified Ellman procedure for assay of cholinesterases in crude enzymatic preparation. Anal Biochem 86 (1978), 324–326.
29. [29] Higashino, K., Takahashi, Y., Yamamura, Y., Release of phenyl acetate esterase from liver microsomes by carbon tetrachloride. Clin Chim Acta 41 (1972), 313–320.
30. [30] Watson, A.D., Berliner, J.A., Hama, S.Y., La Du, B.N., Faull, K.F., Fogelman, A.M., et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96:6 (1995), 2882–2891.
31. [31] Silman, I., Sussman, J.L., Acetylcholinesterase: ‘classical’ and ‘non-classical’ functions and pharmacology. Curr Opin Pharmacol 5:3 (2005), 293–302.
32. [32] Pohanka, M., Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity. Int J Mol Sci 15:6 (2014), 9809–98025.
33. [33] Tan, C.C., Yu, J.T., Wang, H.F., Tan, M.S., Meng, X.F., Wang, C., et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis 41:2 (2014), 615–631.
34. [34] Nava, F., Carta, G., Battasi, A.M., Gessa, G., D(2) dopamine receptors enable delta(9)-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration. Br J Pharmacol 130:6 (2000), 1201–1210.
35. [35] Solinas, M., Scherma, M., Fattore, L., Stroik, J., Wertheim, C., Tanda, G., et al. Nicotinic alpha 7 receptors as a new target for treatment of cannabis abuse. J Neurosci 27:21 (2007), 5615–5620.
36. [36] Egashira, N., Ishigami, N., Mishima, K., Iwasaki, K., Oishi, R., Fujiwara, M., Delta9-Tetrahydrocannabinol-induced cognitive deficits are reversed by olanzapine but not haloperidol in rats. Prog Neuropsychopharmacol Biol Psychiatry 32:2 (2008), 499–506.
37. [37] Friedman, E., Hanin, I., Gershon, S., Effect of tetrahydrocannabinols on 3H-acetylcholine biosynthesis in various rat brain slices. J Pharmacol Exp Ther 196:2 (1976), 339–345.
38. [38] Gessa, G.L., Mascia, M.S., Casu, M.A., Carta, G., Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A. Eur J Pharmacol 327:1 (1997), R1–R2.
39. [39] Acquas, E., Pisanu, A., Marrocu, P., Di Chiara, G., Cannabinoid CB(1) receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo. Eur J Pharmacol 401:2 (2000), 179–185.
40. [40] Acquas, E., Pisanu, A., Marrocu, P., Goldberg, S.R., Di Chiara, G., Delta9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study. Eur J Pharmacol 419:2–3 (2001), 155–161.
41. [41] McPartland, J.M., Duncan, M., Di Marzo, V., Pertwee, R.G., Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol 172:3 (2015), 737–753.
42. [42] Perry, N.S., Houghton, P.J., Theobald, A., Jenner, P., Perry, E.K., In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol 52:7 (2000), 895–902.
43. [43] Darvesh, S., Hopkins, D.A., Geula, C., Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 4:2 (2003), 131–138.
44. [44] Greig, N.H., Utsuki, T., Ingram, D.K., Wang, Y., Pepeu, G., Scali, C., et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci USA 102:47 (2005), 17213–17218.
45. [45] Cervellati, C., Trentini, A., Romani, A., Bellini, T., Bosi, C., Ortolani, B., et al. Serum paraoxonase and arylesterase activities of paraoxonase-1 (PON-1), mild cognitive impairment, and 2-year conversion to dementia: a pilot study. J Neurochem 135:2 (2015), 395–401.
46. [46] Abdel-Salam, O.M.E., Youness, E.R., Mohammed, N.A., Abu Elhamed, W.A., Nuclear factor-Kappa B and other oxidative stress biomarkers in serum of autistic children. Open J Mol Integr Physiol 5 (2015), 18–27.
47. [47] Aviram, M., Rosenblat, M., Billecke, S., Erogul, J., Sorenson, R., Bisgaier, C.L., et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 26:7–8 (1999), 892–904.
48. [48] Nguyen, S.D., Sok, D.E., Oxidative inactivation of paraoxonase1, an antioxidant protein and its effect on antioxidant action. Free Radic Res 37:12 (2003), 1319–1330.
49. [49] Ferrari, A., Tiraferri, I., Palazzoli, F., Licata, M., Tramadol abuse in a binge pattern in a young depressed woman. Eur Addict Res 20:2 (2014), 82–86.
50. [50] Cole, T.B., Jansen, K., Park, S., Li, W.F., Furlong, C.E., Costa, L.G., The toxicity of mixtures of specific organophosphate compounds is modulated by paraoxonase 1 status. Adv Exp Med Biol 660 (2010), 47–60.
51. [51] Jansen, K.L., Cole, T.B., Park, S.S., Furlong, C.E., Costa, L.G., Paraoxonase 1 (PON1) modulates the toxicity of mixed organophosphorus compounds. Toxicol Appl Pharmacol 236:2 (2009), 142–153.